Exscientia raises $100m Series C funding to develop fully autonomous drug design
Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock, but included existing investors: Novo Holdings and Evotec, among others. Exscientia plans to use the funding to advance its technology platforms towards autonomous drug design.